JPMorgan Downgrades Apellis Pharmaceuticals (APLS) to Neutral

April 1, 2026 2:24 AM

JPMorgan analyst Anupam Rama downgraded Apellis Pharmaceuticals (NASDAQ: APLS) from Overweight to Neutral with a price target of $41.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found